-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Chemours, Lowers Price Target to $22

Benzinga·04/14/2025 12:56:46
Listen to the news
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $27 to $22.